Marginal zone lymphoma · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 81 964 | 28d | ~44.1 mo | — | ~2 | ~R 163 929 PFS proxy · indirect | 15 |
Zanubrutinib monotherapy Variant #01 | — | R 65 750 | 28d | — | — | ~2 | ~R 131 500 PFS proxy · indirect | 4 |
Ox-P Variant #01 | — | R 1 601 | 21d | — | — | ~6 | ~R 9 606 indirect | — |
Copanlisib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Umbralisib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
5 of 5 regimens shown